Company Short-Term Debt: Greenwich LifeSciences (GLSI)

Symbol and logo of brand Greenwich LifeSciences (GLSI)

Greenwich LifeSciences (GLSI) is developing oncology immunotherapy, yet a lack of stable revenue and negative cash flow leave the business dependent on external investment. The asset's market value dynamics reflect the current indicator 0.00. Growth prospects rely on the development of the GP2 vaccine, which is preparing for a broad market launch following successful FLAMINGO-01 tests and confirmed efficacy in combating relapses.

Greenwich LifeSciences Inc. (GLSI) - Amount of Current Liabilities from 07/04/2022 to 10/31/2026

GLSI (Greenwich LifeSciences Inc): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Price Greenwich LifeSciences, Inc.|GLSI - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value Greenwich LifeSciences, Inc.|GLSI - Company Buyout Price
- shareholders' equity book value data:
Accounting Value per Share Greenwich LifeSciences|GLSI - Total Net Assets|Market Cap to Net Assets Ratio greenwichlifesciences.com|GLSI - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Total Debt to Capital Greenwich LifeSciences|GLSI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Greenwich LifeSciences|GLSI - Company Aggregate Debts|Debt to Book Capitalization Ratio Greenwich LifeSciences, Inc.|GLSI - Company Long-Term Indebtedness|Company Short-Term Debts Greenwich LifeSciences|Quick Ratio greenwichlifesciences.com
- earnings and valuation multiples indicators:
GLSI - Company Net Income
Analysis of all company metrics:GLSI - Greenwich LifeSciences, Inc.
Manufactured products of Greenwich LifeSciences Inc

Short-term debt reflects the total volume of obligations due within one year. Monitoring current debt allows for an assessment of liquidity risk in the event of a sharp decline in cash flows. This metric aggregates all urgent loans and borrowings, determining the company's dependence on external refinancing. For Greenwich LifeSciences (GLSI), this indicator is critical when financing the development of a vaccine against cancer recurrence. Debt control ensures the stability of research within the immunotherapy segment.

Direct competitors

Olema - Company Short-Term Debts|PBYI - Company Short-Term Debts|Zentalis Pharmaceuticals Inc (ZNTL) - Company Short-Term Debt|MGNX - Short-Term Debt Volume|Company Current Liabilities PSTV|PCSA (Processa Pharma) - Amount of Current Liabilities|Company Current Liabilities EGRX (Eagle Pharmaceuticals)